All In Biotech

NDA 019463 · Bausch and Lomb INC

Timoptic In Ocudose

Timolol Maleate · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Apr 6, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Nov 5, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

306

98 Phase 3, 14 recruiting

FAERS reports

7,686

3,660 serious, 438 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 5, 2025.

INDICATIONS AND USAGE Preservative-free Timolol Maleate Ophthalmic Solution in OCUDOSE is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Preservative-free Timolol Maleate Ophthalmic Solution in OCUDOSE may be used when a patient is sensitive to the preservative in Timolol Maleate Ophthalmic Solution, benzalkonium chloride, or when use of a preservative-free topical medication is advisable.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 5, 1986 Original approval · Type 3 - New Dosage Form
2 products under this application
  • TIMOPTIC IN OCUDOSE · TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT3
  • TIMOPTIC IN OCUDOSE · TIMOLOL MALEATE EQ 0.25% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT3

Clinical trials

Interventional ClinicalTrials.gov studies with "Timolol" as an intervention, any sponsor and status, largest first.

All 306 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure979
  • drug ineffective570
  • eye pain437
  • fatigue405
  • eye irritation350
  • dizziness288
  • diarrhoea283
  • off label use261
  • nausea258
  • vision blurred257
  • headache240
  • ocular hyperaemia227

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004162
2005192
2006154
2007142
2008136
2009132
2010204
2011219
2012312
2013109
2014133
2015238
2016277
2017329
2018346
2019392
20201,432
2021408
2022438
2023513
2024516
2025557
2026344

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,308 on PubMed

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.